相关实验视频

Updated: May 6, 2026

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines

Published on: September 10, 2014

在头部和部瘤干细胞中,塞图西马布和帕克利塔塞尔的药物反应

Vilson Serafim Júnior¹, Glaucia Maria de Mendonça Fernandes¹, Bianca Barbério Bogdan Tedeschi¹

¹Genetics and Molecular Biology Research Unit [UPGEM], Faculty of Medicine of São José do Rio Preto [FAMERP], Avenida Brigadeiro Faria Lima, number 5416, Vila São Pedro, São José do Rio Preto 15090-000, SP, Brazil.

|March 28, 2025

概括

头癌瘤干细胞 (TSCs) 显示对 cetuximab 的耐药性. 与帕克利塔塞尔的联合治疗有效地降低了TSC活力,这表明了头癌的新治疗策略.

科学领域:

在瘤学瘤学.
癌症干细胞生物学
分子向疗法分子向疗法

背景情况:

头癌 (HNC) 是一个重大的全球健康挑战,经常表现出对标准治疗的耐药性.
在HNC中的瘤干细胞 (TSC) 与治疗耐药性,转移和患者的不良结果有关.
了解TSC的分子驱动因素对于开发更有效的HNC疗法至关重要.

研究的目的:

评估塞图西马布和帕克利塔塞尔作为单一疗法和联合疗法对HNC TSCs的疗效.
研究EGFR,NTRK2 (TRKB),KRAS和HIF-1α基因和蛋白质表达在治疗反应中的作用.
确定导致口腔和下癌中TSC耐药性的分子因素.

主要方法:

从SCC-28和FADU细胞系中分离和识别瘤干细胞 (TSCs),使用阿尔代脱酶 (ALDH) 染色.
用MTS试验评估了治疗后的细胞活力,使用 cetuximab 和 paclitaxel.
对EGFR,NTRK2,KRAS和HIF-1α的基因和蛋白质表达水平,通过实时PCR和西方涂抹分析.

主要成果:

无论是TSC还是非TSC,都表现出对单一治疗中西马布的耐药性.
单独使用和与 cetuximab 结合使用的帕克利塔塞尔显著降低了 TSC 的活力.
TSCs表现出KRAS和HIF-1α表达的增加,可能与治疗耐药性相关.

结论:

涉及帕克利塔塞尔的组合疗法在克服HNC中TSC介导的耐药性方面表现有前途.
在TSC中增加KRAS和HIF-1α表达可能是HNC治疗的关键分子标.
这些发现为开发有针对性的组合疗法提供了基础,以改善HNC的临床管理和患者预后.

关键词:

癌症治疗治疗治疗癌症细胞信号传递途径化疗化疗是一种化学疗法.基因表达的基因表达方式头部和部癌症头部和部癌症瘤干细胞是一种瘤干细胞.

更多相关视频

Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics

Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics

Published on: May 11, 2016

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

相关概念视频

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Cancer Stem Cells and Tumor Maintenance

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...